Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Key developments in prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.10.18
Views: 2541

Prof Nicholas James, Prof Karim Fizazi, Prof Matthew Smith, Prof Álvaro Pinto and Dr Mark Beresford

Prof Nicholas James, Prof Karim Fizazi, Prof Matthew Smith, Prof Álvaro Pinto and Prof Mark Beresford meet at ESMO 2018 in Munich to discuss recent advances, and current challenges, in treating prostate cancer.

They discuss highlights from ESMO 2018, including the latest data from STAMPEDE suggesting men with low-metastatic risk prostate cancer may be eligible for radiotherapy, the updated results of a phase III trial of docetaxel-based chemotherapy in high-risk prostate cancer, and the combination of radium-233 with abiraterone acetate and prednisone/prednisolone in the ERA 223 trial.

Other key trials in prostate cancer include PROSPER and LATITUDE.

The challenges of progression risk and how to manage aggressive disease remain, though the advances seen in widening treatment options for different disease stages continues to offer hope for patients.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation